1 Safe-and-Steady Stock Worth Your Attention and 2 We Ignore [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need. Two Stocks to Sell: NeoGenomics (NEO) Rolling One-Year Beta: 0.89 Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ:NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers. Why Should You Sell NEO? Smaller revenue base of $689.2 million means it hasn't achieved the economies of scale that some industry juggernauts enjoy Push for growth has led to negative returns on capital, signaling value destruction, and its shrinking ret
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- 1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off [Yahoo! Finance]Yahoo! Finance
- NeoGenomics (NASDAQ:NEO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 12/3/25 - Form 4
- 12/2/25 - Form SCHEDULE
- 11/28/25 - Form 4
- NEO's page on the SEC website